Federal Alert: Industry Reacts to Trump Psychedelics Executive Order, Calls for MDMA Prioritization

The psychedelics industry is actively responding to a recent federal executive order, with many welcoming its potential to accelerate access to therapies. Advocates are specifically urging the FDA to prioritize MDMA-assisted therapy for PTSD, pushing for fast-tracked review of programs with completed Phase 3 trials. Merchants should closely monitor these federal policy shifts and FDA actions as they will significantly influence the regulatory landscape and market access for therapeutic psychedelics.

The psychedelics community is abuzz with reactions to a recent federal executive order (EO) concerning psychedelics, issued under the Trump administration. While many industry insiders and advocates, such as Genevieve Jurvetson, have expressed enthusiasm for the EO's potential to accelerate access, there's a strong call for specific prioritization.

Key among these calls is the push to fast-track MDMA-assisted therapy for PTSD, particularly Resilient's program which boasts completed Phase 3 trials. Advocates emphasize the urgent need to address the veteran suicide crisis and see MDMA therapy as a top candidate for immediate post-approval patient treatment, urging the FDA to prioritize its review.

Preceding the EO, the DEA had reportedly poured 'cold water' on 'Right to Try' initiatives for psilocybin. Concurrently, the Pentagon has detailed funding for MDMA studies for active-duty service members, indicating a broader federal interest in psychedelic-assisted therapies.

Sentinel Insight